18:30 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases. Cabaletta's co-founders include Michael Milone, an...
20:09 , Nov 8, 2018 |  BC Extra  |  Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases. Cabaletta's co-founders include Michael Milone, an...
16:29 , Sep 21, 2018 |  BC Week In Review  |  Financial News

Ahead of Phase III mucositis study, Galera raises $150M

Galera Therapeutics Inc. (Malvern, Pa.) raised a combined $150 million in a $70 million series C round and $80 million royalty deal led by new investor Clarus. The fund-raising comes ahead of Galera's planned Phase...
18:17 , Sep 19, 2018 |  BC Extra  |  Financial News

Ahead of Phase III mucositis study, Galera raises $150M

Galera Therapeutics Inc. (Malvern, Pa.) raised a combined $150 million in a $70 million series C round and $80 million royalty deal led by new investor Clarus. The fund-raising comes ahead of Galera's planned Phase...
14:42 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Precision BioSciences raises $110M in series B

Genome editing company Precision BioSciences Inc. (Durham, N.C.) raised $110 million in an oversubscribed series B round led by new investor ArrowMark Partners. Other new Investors included Franklin Templeton, Cowen Healthcare Investments, Brace Pharma Capital,...
19:46 , Jun 26, 2018 |  BC Extra  |  Financial News

Precision BioSciences raises $110M in series B

Genome editing company Precision BioSciences Inc. (Durham, N.C.) raised $110 million in an oversubscribed series B round led by new investor ArrowMark Partners. Other new Investors included Franklin Templeton, Cowen Healthcare Investments, Brace Pharma Capital,...
18:44 , Mar 9, 2018 |  BioCentury  |  Finance

Genetics prevail

Prevail Therapeutics Inc.’s focus on genetic subpopulations of patients with neurodegenerative diseases led EcoR1 Capital to join the newco’s tranched $75 million series A round. The round’s investors included OrbiMed Advisors, Pontifax Fund, RA Capital...
18:25 , Mar 9, 2018 |  BC Week In Review  |  Financial News

Prevail raises $75M series A

Gene therapy and neurodegenerative disease company Prevail Therapeutics Inc. (New York, N.Y.) raised $75 million on March 8 in a series A round from OrbiMed Advisors, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds,...
12:08 , Mar 8, 2018 |  BC Extra  |  Financial News

Prevail raises $75 million series A

Prevail Therapeutics Inc. (New York, N.Y.) raised $75 million in a series A round from OrbiMed Advisors, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners, Boxer Capital, Adage Capital Management and Alexandria...
21:41 , Sep 29, 2017 |  BC Week In Review  |  Financial News

Engage, Integra raise venture financings

Epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million on Sept. 27 in a series A round...